fda approval status of dihexa EllieMD Dihexa (also known as PNB-0408)

Dihexas neuroprotective properties were attributed to its ability to enhance mitochondrial function, reduce oxidative stress, and modulate signaling pathways associated with cell survival

In animal models, preclinical work has also documented antinociceptive effects (attributed to indirect Met-enkephalin release [7]), antioxidant enzyme stimulation [11], and inhibition of hypothalamic somatostatin secretion [8]

Similarly, a phase III clinical trial revealed no significant improvements in clinical benefits in first-line chemotherapy for HER2-negative and c-Met-positive advanced gastroesophageal adenocarcinoma (GEC)

doi: 10.1002/ana.410390106